A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Summary

The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.

Timeline

Start

2023-12-06

Primary completion

2025-04-01

Completion

2025-05-06

Outcome

Missed primary endpoint

registry analysis (superiority test); LY3972406 vs Placebo; p = 0.316; Odds Ratio (OR) 3.4 (95% CI 0.3 to 40.4); Cochran-Mantel-Haenszel NCT06176768 ↗

Drugs

Indications